NFKB1 and metabolic dysfunction-associated steatotic liver disease: Additionally, SCFAs exhibit anti-inflammatory effects by suppressing the NF-κB signaling pathway, reducing the expression of inflammatory cytokines, and alleviating liver inflammation in MASLD [104].